INC280: Clinical Trials

23 trials of INC280, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

9 completed, 8 terminated, 2 recruiting, 2 withdrawn. 23 Phase 2, 4 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 223Completed 9, Terminated 8, Recruiting 2, Withdrawn 2, Active not recruiting 1, Suspended 1
Phase 14Terminated 2, Completed 1, Recruiting 1

Follow INC280: new trials by email Literature Review of INC280 trials Research Report on INC280

Trials (filtered) newest first · largest first

All 23 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Biospecimen Collection, Capmatinib, Computed Tomography - Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Phase 2RecruitingSWOG Cancer Research Network662023-05-052026-06-03
Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC
capmatinib - Non-small Cell Lung Cancer
Phase 2TerminatedNovartis Pharmaceuticals42022-08-102025-10-16
Combination of Capmatinib + Spartalizumab in Advanced Oesogastric Adenocarcinoma
Capmatinib, Spartalizumab - Oesophageal Adenocarcinoma, Gastric Adenocarcinoma
Phase 2SuspendedAssistance Publique - Hôpitaux de Paris902022-03-222023-02-03
Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation
Capmatinib - Non-Small Cell Lung Cancer (NSCLC)
Phase 2CompletedNovartis Pharmaceuticals362021-05-172026-03-31
Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations
Spartalizumab, Capmatinib, spartalizumab placebo - Carcinoma, Non-Small-Cell Lung
Phase 2TerminatedNovartis Pharmaceuticals312020-08-192024-10-09
Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%
Capmatinib, Pembrolizumab - Non-small Cell Lung Cancer (NSCLC)
Phase 2TerminatedNovartis Pharmaceuticals762020-01-222024-10-09
Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer
Capmatinib, Spartalizumab, Docetaxel - Carcinoma, Non-Small-Cell Lung
Phase 2CompletedNovartis Pharmaceuticals182018-12-262022-01-24
Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
PDR001, LAG525, INC280 - Melanoma
Phase 2CompletedNovartis Pharmaceuticals1962018-09-102024-06-18
Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)
INC280 - Carcinoma, Non-Small-Cell Lung Cancer
Phase 2WithdrawnNovartis Pharmaceuticals2018-07-312018-07-26
Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone
Capmatinib, Nazartinib, Gefitinib - Advanced Solid Tumors Which Are cMET-dependent
Phase 2Active not recruitingNovartis Pharmaceuticals292017-07-042026-09-09
Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma
INC280, Placebo - Advanced Hepatocellular Carcinoma
Phase 2WithdrawnNovartis Pharmaceuticals2016-12-012016-09-01
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
Ribociclib, Topotecan, Temozolomide - Pediatric Cancer
Phase 1 / Phase 2RecruitingGustave Roussy, Cancer Campus, Grand Paris4722016-08-032026-07-10
Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC
Spartalizumab, Capmatinib - Advanced Hepatocellular Carcinoma
Phase 1 / Phase 2CompletedNovartis Pharmaceuticals892016-06-152023-07-03
Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)
Capmatinib - Carcinoma, Non-Small-Cell Lung
Phase 2CompletedNovartis Pharmaceuticals3732015-06-112024-03-20
Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma
Capmatinib, Ceritinib, Entrectinib - ALK Fusion Protein Expression, BRAF wt Allele
Phase 2TerminatedUniversity of California, San Francisco12015-03-262020-01-27
Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer
EGF816, INC280, Nivolumab - Non Small Cell Lung Cancer
Phase 2TerminatedNovartis Pharmaceuticals642015-02-092022-02-28
A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer
BYL719, INC280, LDK378 - Adenocarcinoma Lung Cancer; Squamous Cell Lung Carcinoma
Phase 2CompletedNovartis Pharmaceuticals662015-01-202020-12-16
Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.
Capmatinib, Nazartinib - Non Small Cell Lung Cancer
Phase 1 / Phase 2TerminatedNovartis Pharmaceuticals1772015-01-132023-06-18
LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma
LGX818, MEK162, LEE011 - Melanoma
Phase 2CompletedPfizer1582014-07-232024-03-05
A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer
INC280 - Kidney Cancer
Phase 2CompletedNational Cancer Institute (NCI)202014-01-242023-03-21

Showing 20 of 23. Sign in to see all of them.

Conditions studied

Carcinoma, Non-Small-Cell Lung (12)  ·  Adenocarcinoma of Lung (4)  ·  Lung Neoplasms (4)  ·  Melanoma (3)  ·  Neoplasm Metastasis (2)  ·  Adenocarcinoma Of Esophagus (1)  ·  Brain Neoplasms (1)  ·  Carcinoma (1)  ·  Glioblastoma (1)  ·  Gliosarcoma (1)  ·  Kidney Neoplasms (1)  ·  Liver Neoplasms (1)  ·  Neoplasms (1)  ·  Noonan Syndrome 6 (1)

Sponsors

Novartis Pharmaceuticals (17)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Gustave Roussy, Cancer Campus, Grand Paris (1)  ·  National Cancer Institute (NCI) (1)  ·  Pfizer (1)  ·  SWOG Cancer Research Network (1)  ·  University of California, San Francisco (1)

Countries

United States (14)  ·  France (13)  ·  Germany (13)  ·  Spain (13)  ·  Italy (11)  ·  Australia (7)  ·  Canada (7)  ·  Netherlands (7)  ·  Belgium (6)  ·  China (6)  ·  Singapore (6)  ·  South Korea (6)  ·  Switzerland (5)  ·  Taiwan (5)  ·  Hong Kong (4)

Top investigators

Adil Daud (1)  ·  Birgit Geoerger, MD (1)  ·  Ramaprasad Srinivasan, M.D. (1)  ·  Sarah B Goldberg (1)

Results publications

PMID 26825170, PMID 30156984, PMID 31538815, PMID 31776899, PMID 31853265, PMID 32877583, PMID 33892407, PMID 34347542, PMID 34376578, PMID 34543871, PMID 35292802, PMID 36822130, PMID 38617599, PMID 38763104, PMID 38986421, PMID 39362249, PMID 41838385, PMID 41914670, PMID 42686334

NIH funding

2014 (3), 2018 (2), 2019 (2), 2015 (1), 2016 (1), U10CA180888 (1)